Search results
Bull Market and Beyond: 2 Stocks Just Waiting to Soar | The Motley Fool
The Motley Fool· 2 days agoLet's consider two such stocks: Moderna (MRNA 7.13%) and DexCom (DXCM -1.65%). Moderna is one of the...
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
Motley Fool via Yahoo Finance· 1 day agoThe Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Moderna. The...
Moderna says FDA delaying decision on RSV vaccine approval, shares fall
Investing.com· 6 days agoModerna says FDA delaying decision on RSV vaccine approval, shares fall
FDA Delays Decision on Moderna RSV Shot by 3 Weeks
Barrons.com· 5 days agoThe agency was originally scheduled to announce its call on Sunday. The company said it hadn’t flagged any issues with the drug’s safety, efficacy, or...
Stocks Log Weekly Gains in Hot Start to May
The Wall Street Journal· 5 days agoThe S&P 500 inched 0.2% higher, while the tech-heavy Nasdaq Composite edged a hair lower. The May performance marks a reversal from April, when...
These Stocks Moved the Most Today: Novavax, Akamai, Sweetgreen, Taiwan Semi, Moderna, Gen Digital,...
Barrons.com· 5 days agoNovavax stock surged after the vaccine maker signs a $1.2 billion licensing deal with France’s...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks· 3 days agoFree Report) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345.
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 1 day agoIt will be important to watch how Pfizer stock performs as the company shores up its pipeline and...
3 Hot Stocks to Buy That Still Look Undervalued
Morningstar· 2 days agoHere at Morningstar, we talk a lot about the dangers of chasing performance, or buying a stock, ETF, or fund because it’s on a hot streak. Morningstar...
Why This Small Diagnostics Name Is 'A Stock To Focus On'
Investor's Business Daily· 5 days agoThe March quarter benefited from increases in test volume and average selling price for tests in the...